MDR Candida NGS: Introduction, Principle, Test Requirements

Introduction of MDR Candida NGS

Table of Contents

MDR Candida NGS refers to the use of Next-Generation Sequencing for the detection, identification, and resistance gene profiling of multidrug-resistant (MDR) Candida species, such as Candida auris, Candida glabrata, and others resistant to azoles, echinocandins, or polyenes.

Next-generation sequencing (NGS) allows comprehensive genetic analysis of Candida species directly from clinical isolates or specimens. In MDR Candida, it helps:

Identify the species accurately, even in mixed infections.
Detect mutations in resistance-associated genes (e.g., ERG11, FKS1, FKS2).
Track clonal outbreaks and understand transmission dynamics.

Principle

NGS works by:

Fragmenting the fungal DNA.
Ligating adaptors and preparing libraries.
Massively parallel sequencing of millions of DNA fragments.
Bioinformatics analysis to map reads to reference genomes.

It identifies point mutations, insertions/deletions, and resistance gene expression patterns, especially in ERG11 (azoles), FKS1/2 (echinocandins), and CDR1/CDR2 (efflux pumps).

Test Requirements

Specimen:

Clinical isolates (e.g., from blood, catheter, tissue)
Pure cultures (e.g., SDA/BHI growth)

Reagents/Materials:

DNA extraction kit
Library preparation kit
Indexed barcodes
Sequencing platform (Illumina, Ion Torrent, Oxford Nanopore)
Bioinformatics tools (Galaxy, CLC Genomics, Geneious)

Procedure

DNA Extraction:
- From Candida isolate using fungal-specific kits
Library Preparation:
- DNA fragmentation
- End repair, adaptor ligation
- Size selection and amplification
Sequencing:
- Load prepared libraries onto the NGS platform
- Generate millions of reads per sample
Data Analysis:
- Quality check and trimming
- The map reads to reference Candida genomes
- Identify mutations in resistance genes (e.g., ERG11, FKS1, CDR1/CDR2)
Reporting:
- Identify species, resistance genes, and sequence type (ST)

Result Interpretation

Result	Interpretation
Species ID	Confirms Candida auris, C. glabrata, etc.
Resistance Mutations	ERG11 Y132F, FKS1 S645P → drug resistance
No Resistance Genes Detected	Likely susceptible strain
Multilocus Sequence Typing (MLST)	For outbreak tracking and clonal relatedness

Clinical Significance

Precise species identification, even among cryptic or emerging species.
Enables the detection of resistance mechanisms before phenotypic AST.
Helps guide targeted antifungal therapy.
Tracks nosocomial outbreaks and MDR transmission.
Useful in epidemiological surveillance and infection control.

Keynotes

MDR Candida is a major healthcare concern, especially C. auris
NGS provides faster and deeper insights than conventional methods
Results must be interpreted with clinical correlation
Requires specialized infrastructure and bioinformatics expertise
Can be used in conjunction with AFST, MALDI-TOF, PCR, and whole genome sequencing

MDR Candida NGS:Introduction, Principle, Test Requirements, Procedure, Result-Interpretation, Clinical Significance, and Keynotes